Description:
 
Background
Efforts to use magnetic resonance imaging (MRI) to produce reproducible biomarkers for mild traumatic brain injury (TBI) have proven ineffective. 
In many cases there are reported increases in perivascular space, but no reliable imaging method exists to quantify the volume spatially.
 
Technology Overview
This technology uses a method called a paramagnetic contrast agent (CA), introduced into the perivascular space (for example, by intrathecal injection), to specifically enhance the contrast of the cerebral spinal fluid (CSF) throughout the entire central nervous system (CNS).
Statistically significant abnormalities have been found by comparing healthy rats to those of the relevant disease model or indication.
 
Benefits
- The confinement and long residence time of the SPION ferumoxytol to the perivascular space enables longitudinal and highly accurate measurements
- The signal quantification with the QUTE-CE method is unique and was previously not indicated for CSF or perivascular space measurements
 
Applications
- Pharmaceuticals
- Clinics
 
Opportunity
- License
- Partnering
- Research Collaboration
Patent Information:
Category(s):
Imaging
For Information, Contact:
Mark Saulich
Associate Director of Commercialization
Northeastern University
m.saulich@northeastern.edu
Inventors:
Keywords:
Diagnostics
Imaging Technology
MRI contrast agent